ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Novo signs two drug pacts

March 20, 2006 | APPEARED IN VOLUME 84, ISSUE 12

Novo Nordisk has licensed antibody technology from Durham, N.C.-based Argos Therapeutics for the development of drugs to treat systemic immune disorders. The deal could be worth up to $69 million for Argos, which will receive up-front and milestone payments, as well as royalties on any drugs developed through its technology. Using its dendritic cell-based technology platform, Argos has found monoclonal antibodies that target INF-alpha, which is vital to the onset and maintenance of lupus. Separately, Novo has signed an agreement to study the use of Nastech Pharmaceutical's molecular biology-based drug delivery technology with several of its compounds.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment